Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
New Microbes New Infect. 2021 Jul;42:100895. doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.
自2013年以来，索磷布韦和达卡他韦已成功用于丙型肝炎治疗。不同研究表明，索磷布韦可抑制包括黄病毒科和披膜病毒科在内的其他正链RNA病毒的RNA聚合酶。丙型肝炎病毒RNA聚合酶与严重急性呼吸综合征冠状病毒2之间的同源性也已得到证实。可以推测索磷布韦和达卡他韦作为治疗2019冠状病毒病患者的潜在选择及其疗效。
